Sanofi, Seikagaku, Zimmer autoimmune news

The U.S. District Court for the District of Massachusetts granted a motion from Sanofi for a preliminary injunction preventing Seikagaku from selling its Gel-One at a price under $547.60, which is the market price of competitor product Synvisc-One from Sanofi's Genzyme Corp. subsidiary. The injunction will be in effect until the court enters a final judgment in the trial, which is scheduled for April. Last April, Genzyme filed a suit against Seikagaku and Zimmer claiming that Gel-One infringes U.S. patent No. 5,399,351, which covers the use of biocompatible viscoelastic gel slurries, including Synvisc-One and Synvisc hylan G-F 20 (see BioCentury, April 25, 2011). ...